Efficacy of antibiotic therapy for SAPHO syndrome is lost after its discontinuation: an interventional study

Table 4 Activity scores in weeks 1, 16 and 28 for SAPHO patients treated with antibiotics

Activity score	Week 1	Week 16	Week 28	Pvalue (95% confidence interval)
Skin	2.5 ± 0.5 (1 to 6)	1.2 ± 0.5 (0 to 4)	1.7 ± 0.5 (0 to 5)	0.01 (1.31 to 2.77)^a
				0.11 (-1.43 to -0.24)^b
				0.09 (-0.17 to 1.84)^c
Osteitis	3.5 ± 0.4 (1 to 6)	1.9 ± 0.4 (0 to 4)	2.7 ± 0.5 (0 to 6)	0.01 (1.30 to 2.63)^a
				0.01 (-1.43 to -0.24)^b
				0.15 (-0.31 to 1.81)^c
Erythrocyte sedimentation rate	24.8+-3.3 (9 to 45)	23.3+-2.8 (11 to 36)	25.7+-2.4 (12 to 40)	0.43 (-0.13 to 0.30)^a
				0.35 (-0.33 to 0.13)^b
				0.34 (-0.20 to 0.53)^c
MRI	1.6 ± 0.1 (0 to 2)	1.2 ± 0.1 (0 to 2)	1.4 ± 0.2 (1 to 2)	0.01 (0.44 to 0.89)^a
				0.08 (-0.54 to 0.04)^b
				0.19 (-0.15 to 0.65)^c
Health Assessment Score	3.8 ± 0.4 (2 to 6)	2.2 ± 0.3 (0 to 6)	3.3 ± 0.4 (1 to 6)	0.01 (1.51 to 2.79)^a
				0.02 (2.02 to 0.32)^b
				0.11 (-0.16 to 1.32)^c

Treatment finishing in week 16. Data presented as the mean ± standard error (range); n = 12. ^aPairwise test (value week 1 vs. value week 16). ^bPairwise test (value week 16 vs. value week 28). ^cPairwise test (value week 1 vs. value week 28).